Recent Security Class Actions

BioLineRx Ltd. American Depositary Shares (NASDAQ: BLRX)

Company Name:BioLineRx Ltd. American Depositary Shares
Stock Symbol:NASDAQ: BLRX
Class Period Start:02/23/2021
Class Period End (inclusive):09/19/2022
Filing Deadline:03/06/2023

According to the Complaint, it is alleged that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose, among other things, that: (1) the Company was not well financed to develop Motixafortide while at the same time advancing other pipeline programs; (2) BioLine would require a loan from Kreos Capital VII Aggregator SCSP in an aggregate principal amount of up to $40 million and then also would require a $15M securities offering to facilitate the commercial launch of Motixafortide; and (3) as a result of the foregoing, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.